Trial Protocol ID USOR 21455_WO43571_heredERA

Trial Description

A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Giredestrant in Combination with Phesgo versus Phesgo after Induction Therapy with Phesgo+Taxane in Patients with Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally-Advanced or Metastatic Breast Cancer

Contact us regarding Clinical Trials at or call us at 877-664-7724


  • Jeanine L Werner, M.D.

Disease Types


  • Roche Laboratories, Inc. NCT ID

  • NCT05296798